MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

MDT

100.71

-0.28%↓

135.73

+0.63%↑

VEEV

223.72

+0.88%↑

HQY

85.01

+1.03%↑

NEOG

+1.94%↑

Home・Aandelen Lijst・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Gesloten

4.08 0.25

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.9699999999999998

Max

4.11

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -7.7M
Verkoop	-10M 529K
Winstmarge	-1,463.516
Werknemers	44
EBITDA	-10M -7.7M

Dividenden
By Dow Jones
Volgende Winsten	26 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-99M 781M
Vorige openingsprijs	3.83
Vorige sluitingsprijs	4.08

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

3.255 / 3.365 Steun & Weerstand

Arbutus Biopharma Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 jan 2026, 23:49 UTC

Populaire aandelen

Stocks to Watch: Agilysys, Nucor, Humana, UnitedHealth

26 jan 2026, 23:09 UTC

Belangrijke Marktbewegers

Health Insurers' Shares Fall After Government Proposes Flat Medicare Advantage Rate

26 jan 2026, 23:52 UTC

Marktinformatie

Gold's Path of Least Resistance Still Looks Higher, Technical Analysis Shows -- Market Talk

26 jan 2026, 23:46 UTC

Marktinformatie

Nikkei May Decline as Yen's Rebound Raises Caution Over Earnings -- Market Talk

26 jan 2026, 23:37 UTC

Marktinformatie

Gold Rises Amid Concerns Over Tariffs -- Market Talk

26 jan 2026, 22:41 UTC

Marktinformatie

Australian 4Q CPI To Provide Smoking Gun For Hike -- Market Talk

26 jan 2026, 22:26 UTC

Winsten

Karoon Expects Capex of US$110 Million-US$135 Million in 2026

26 jan 2026, 22:26 UTC

Winsten

Karoon Expects Operating Costs to Fall Once Transition of Bauna FPSO Operatorship Completes

26 jan 2026, 22:25 UTC

Winsten

Karoon Energy Expects Unit Production Cost of US$12-US$15/BOE in 2026

26 jan 2026, 22:25 UTC

Winsten

Karoon Energy Expects Output to Rise in 2H Following Bauna Investment Program

26 jan 2026, 22:25 UTC

Winsten

Karoon Energy Expects Output of 8.1 Million-9.2 Million BOE in 2026

26 jan 2026, 22:24 UTC

Winsten

Karoon Energy 4Q Sales Revenue US$156.1 Million

26 jan 2026, 22:23 UTC

Winsten

Karoon Energy 4Q Sales Volumes 2.65 Million BOE, Up 5% on Quarter

26 jan 2026, 22:23 UTC

Winsten

Karoon Energy: Bauna FPSO Efficiency Increased to 98.8%

26 jan 2026, 22:23 UTC

Winsten

Karoon Energy FY Oil, Natural Gas Production 10.3 Million BOE

26 jan 2026, 22:22 UTC

Winsten

Karoon Energy 4Q Oil, Natural Gas Production 2.37 Million BOE

26 jan 2026, 22:05 UTC

Acquisities, Fusies, Overnames

Fortescue: Alta Copper Shareholders Approve Takeover

26 jan 2026, 22:02 UTC

Acquisities, Fusies, Overnames

Senate Antitrust Panel Chair Raises Concerns Over Netflix-Warner Deal -- WSJ

26 jan 2026, 21:50 UTC

Marktinformatie

Winsten

Financial Services Roundup: Market Talk

26 jan 2026, 21:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

26 jan 2026, 21:34 UTC

Winsten

Nucor: Steel Products Segment Expected Improved Earnings in 1Q Due to Increased Volumes on Stable Pricing >NUE

26 jan 2026, 21:34 UTC

Winsten

Nucor: Steel Mills Segment Expected Increase Is Due to Higher Volumes and Higher Realized Prices Across All Major Pdt Categories >NUE

26 jan 2026, 21:34 UTC

Winsten

Nucor: Raw Materials Segment Is Expected to Have Increased Earnings in 1Q >NUE

26 jan 2026, 21:34 UTC

Winsten

Nucor: 1Q Earnings Expected to Increase Across All Three Operating Segments, With the Largest Increase in Steel Mills Segment >NUE

26 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Eaton Stock Rises on Spin-Off Plan. Why It's Going All-In on Planes and AI Data Centers. -- Barrons.com

26 jan 2026, 21:30 UTC

Winsten

Nucor 4Q Sales $7.69B >NUE

26 jan 2026, 21:30 UTC

Winsten

Nucor 4Q Net $378M >NUE

26 jan 2026, 21:30 UTC

Winsten

Nucor 4Q Steel Mills Total Shipments 5.91M Tons >NUE

26 jan 2026, 21:30 UTC

Winsten

Nucor 4Q Total Tons Shipped to Outside Customers Down 9% >NUE

26 jan 2026, 21:30 UTC

Winsten

Nucor 4Q EPS $1.64 >NUE

Peer Vergelijking

Prijswijziging

Arbutus Biopharma Corp Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Arbutus Biopharma Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.255 / 3.365Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.